LIFR and prostate carcinoma: For instance, Lv et al. identified that KMT2D expression could promote prostate cancer proliferation and metastasis via the epigenetic transcriptional activation of leukemia inhibitory factor receptor (LIFR) and Kruppel-like factor-4 (KLF4), respectively via the PI3K/Akt and epithelial–mesenchymal transition-associated (EMT-associated) pathways [8].